Could a common allergy spray help schizophrenia?

NCT ID NCT03794076

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether cromoglicate, a nasal spray used for allergies, can improve symptoms in people with schizophrenia or schizoaffective disorder. Researchers will give 160 adults either the active spray or a placebo, in addition to their usual medication. The goal is to see if it reduces positive symptoms like hallucinations or delusions.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
cromoglicate (NasalCrom) nasal spray
What this could lead to
If it works, this could offer a new add-on treatment to help control schizophrenia symptoms with fewer side effects.
What could go wrong
This is an early Phase 1/2 trial, so it is small and mainly tests safety. It may not show clear benefit, and the effect could be small or absent.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SCHIZO AFFECTIVE DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University of Pittsburgh

    RECRUITING

    Pittsburgh, Pennsylvania, 15213, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.